1. Home
  2. THCH vs ACET Comparison

THCH vs ACET Comparison

Compare THCH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TH International Limited Ordinary shares

THCH

TH International Limited Ordinary shares

N/A

Current Price

$2.10

Market Cap

58.9M

Sector

Finance

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.24

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THCH
ACET
Founded
2018
1947
Country
China
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.9M
69.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
THCH
ACET
Price
$2.10
$7.24
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
7.7K
174.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.82
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.69
$0.45
52 Week High
$3.50
$9.05

Technical Indicators

Market Signals
Indicator
THCH
ACET
Relative Strength Index (RSI) 55.81 53.18
Support Level $2.09 $0.62
Resistance Level $2.71 $8.46
Average True Range (ATR) 0.07 0.52
MACD 0.05 -0.07
Stochastic Oscillator 67.49 73.50

Price Performance

Historical Comparison
THCH
ACET

About THCH TH International Limited Ordinary shares

TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: